API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://recalls-rappels.canada.ca/en/alert-recall/donepezil-10-mg-tablets-affected-lot-may-contain-over-sized-tablets
https://www.prnewswire.com/news-releases/corium-announces-publication-of-favorable-adlarity-donepezil-transdermal-system-skin-irritation-clinical-trial-data-301924112.html
https://www.contractpharma.com/contents/view_breaking-news/2023-08-10/corium-lotus-pharmaceutical-partner-on-alzheimer-s/?widget=listSection
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216901
https://www.prnewswire.com/news-releases/corium-announces-publication-of-adlarity-donepezil-transdermal-system-clinical-trial-data-drug-exposure-equivalent-to-oral-donepezil-with-favorable-gi-side-effect-profile-301626829.html
https://www.globenewswire.com/news-release/2022/03/16/2404258/16626/en/KemPharm-Earns-1-975-Million-Fee-from-Corium-Following-FDA-Approval-of-the-Corium-Product-ADLARITY-donepezil-transdermal-system.html
https://www.prnewswire.com/news-releases/corium-receives-fda-approval-of-adlarity-donepezil-transdermal-system-for-treatment-of-patients-with-alzheimers-disease-301501426.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-8-2021-1631096882.pdf
https://www.business-standard.com/article/pti-stories/drug-makers-granules-india-jubilant-cadista-recall-products-in-us-market-121091200339_1.html
https://www.reuters.com/article/us-health-neurology-drug-costs/people-often-skip-neurological-meds-when-out-of-pocket-costs-rise-idUSKBN20D2QG?feedType=RSS&feedName=healthNews
https://www.federalregister.gov/documents/2019/12/02/2019-25946/morton-grove-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-21-abbreviated-new-drug
https://endpts.com/what-does-the-past-generation-of-failure-in-alzheimers-rd-look-like-in-one-slide/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205269
http://www.koreabiomed.com/news/articleView.html?idxno=3686
https://www.biospectrumasia.com/news/25/11032/eisai-partners-with-chong-kun-dang-for-drug-sales.html
https://www.in-pharmatechnologist.com/Article/2017/11/20/Corium-close-to-partnering-on-transdermal-Alzheimer-s-drug
http://www.biospace.com/News/axovants-much-hyped-alzheimers-drug-flunks-phase/470498/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204609
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-namzaric-memantine-hydrochloride-extended-release-and-donepezil-hydrochloride-1503543880.pdf
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-May-3-2017-1493786253.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202410
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208328
http://www.fiercepharma.com/pharma/eisai-s-lenvima-moves-toward-nexavar-showdown-phase-3-liver-cancer-win
http://www.fiercebiotech.com/biotech/allergan-chases-high-dose-low-side-effects-alzheimer-s-combo-biotech-buy
http://www.fiercepharma.com/marketing/new-indication-for-allergan-s-namrazic-led-to-new-creative-for-common-bonds-campaign
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204831
http://www.prnewswire.com/news-releases/allergan-and-adamas-announce-us-availability-of-new-dosage-strengths-for-namzaric-memantine-and-donepezil-hydrochlorides-extended-release-for-the-treatment-of-moderate-to-severe-alzheimers-disease-300332399.html
http://www.prnewswire.com/news-releases/allergan-and-adamas-announce-new-expanded-indication-for-namzaric-memantine-and-donepezil-hydrochlorides-extended-release-for-the-treatment-of-moderate-to-severe-alzheimers-disease-300300474.html
https://www.pharmacompass.com/pdf/news/unichem-labs-generic-donepezil-approved-in-us-for-cognition-in-alzheimers-1467005714.pdf
http://www.fiercepharma.com/pharma-asia/eisai-gains-philippines-approval-for-aricept-new-license
http://twofourinsight.com/indicus-generic-aricept-approval-reveals-potential-us-government-sales/
https://www.pharmacompass.com/pdf/news/indicus-pharmas-generic-donepezil-hcl-approved-in-us-to-treat-dementia-1460632945.pdf
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-launches-generic-aricept-tablets-in-us-market/articleshow/51631363.cms
http://www.fiercebiotech.com/story/chase-pharma-raises-12m-alzheimers-rd/2016-03-29
http://www.fiercepharmamarketing.com/story/pharmas-dtc-ad-spending-soars-past-5-billion-2015/2016-03-07
http://www.prnewswire.com/news-releases/ani-pharmaceuticals-and-dexcel-announce-fda-approval-of-donepezil-hydrochloride-23mg-tablets-300225053.html
https://www.pharmacompass.com/pdf/news/dexcel-pharmas-generic-donepezil-hydrochloride-approved-in-us-to-treat-mild-to-moderate-dementia-1456221344.pdf
http://www.pharmatimes.com/Article/16-01-19/Dementia_prescriptions_six_times_higher_than_a_decade_ago.aspx
http://www.fiercepharmaasia.com/story/singapores-taurx-mulls-nasdaq-ipo-and-sees-future-alzheimers-treatment/2016-01-06
http://www.fiercebiotech.com/story/adamas-soars-its-parkinsons-drug-comes-through-phase-iii/2015-12-23
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/56268a-eng.php
http://www.fiercepharma.com/story/struggling-eisai-looks-help-china-new-generics-deal/2015-12-03
http://www.fiercepharmamarketing.com/story/allergan-counting-january-formulary-boost-jump-start-namzaric-launch/2015-11-11
http://www.fiercepharma.com/story/allergan-shut-down-namenda-hard-switch-takes-it-scotus/2015-11-10
https://www.pharmacompass.com/pdf/news/lupins-generic-donepezil-hcl-approved-in-us-for-alzheimer-1446812873.pdf